{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T20:30:20Z","timestamp":1783888220573,"version":"3.55.0"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,2,1]],"date-time":"2017-02-01T00:00:00Z","timestamp":1485907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1016\/j.trim.2016.11.004","type":"journal-article","created":{"date-parts":[[2016,11,22]],"date-time":"2016-11-22T20:16:44Z","timestamp":1479845804000},"page":"42-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Randomized trial of rATg\/Daclizumab vs. rATg\/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up"],"prefix":"10.1016","volume":"40","author":[{"given":"Gaetano","family":"Ciancio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey J.","family":"Gaynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Sageshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren","family":"Kupin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3388-5648","authenticated-orcid":false,"given":"Adela","family":"Mattiazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lissett","family":"Tueros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Vianna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"George W.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2016.11.004_bb0005","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000101290.20629.DC","article-title":"A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil versus cyclosporine (NEORAL)\/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0015","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1097\/01.tp.0000203894.53714.27","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate versus cyclosporine\/sirolimus in renal transplantation: three-year analysis","volume":"81","author":"Ciancio","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0020","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1681\/ASN.2011010006","article-title":"Randomized trial of immunosuppressive regimens in renal transplantation","volume":"22","author":"Guerra","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2016.11.004_bb0025","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/01.tp.0000165847.05787.08","article-title":"A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring","volume":"80","author":"Ciancio","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0030","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1399-0012.2007.00774.x","article-title":"A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24months of follow up","volume":"22","author":"Ciancio","year":"2008","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.trim.2016.11.004_bb0035","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1016\/j.transproceed.2010.08.045","article-title":"Randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in living donor renal transplantation","volume":"42","author":"Ciancio","year":"2010","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2016.11.004_bb0040","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1097\/01.TP.0000441089.39840.66","article-title":"Randomized trial of three induction antibodies in kidney transplantation: long-term results","volume":"97","author":"Ciancio","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0045","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/TP.0b013e3181734b4a","article-title":"Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab\/thymoglobulin: one year follow-up","volume":"86","author":"Ciancio","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0050","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/TP.0b013e3182003d76","article-title":"Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four year analysis","volume":"91","author":"Ciancio","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0055","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1111\/j.1600-6143.2012.04235.x","article-title":"Advantage of rapamycin over mycophenolate mofetil when used with tacrolimus for simultaneous pancreas kidney transplants: randomized single-center trial at 10years","volume":"12","author":"Ciancio","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2016.11.004_bb0060","doi-asserted-by":"crossref","first-page":"E132","DOI":"10.1111\/j.1399-0012.2010.01360.x","article-title":"Addition of anti-CD25 to thymoglobulin for induction therapy: delayed return of peripheral blood CD25 positive population","volume":"25","author":"Sageshima","year":"2011","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.trim.2016.11.004_bb0065","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1097\/00007890-199904150-00013","article-title":"A randomized, double-blinded comparison of thymoglobulin versus ATGAM for induction immunosuppressive therapy in adult renal transplant recipients","volume":"67","author":"Brennan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0070","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1097\/01.TP.0000081042.67285.91","article-title":"A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients","volume":"76","author":"Goggins","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0075","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1111\/j.1600-6143.2005.01051.x","article-title":"Prednisone-free maintenance immunosuppression \u2013 a 5-year experience","volume":"5","author":"Matas","year":"2005","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2016.11.004_bb0080","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2016.11.004_bb0085","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1681\/ASN.2008101037","article-title":"Daclizumab versus antithymocyte globulin in high-immmunological-risk renal transplant recipients","volume":"20","author":"Noel","year":"2009","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2016.11.004_bb0090","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1159\/000351643","article-title":"Thymoglobulin and its use in renal transplantation: a review","volume":"37","author":"Thiyagarajan","year":"2013","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.trim.2016.11.004_bb0095","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/01.tp.0000268084.64888.f3","article-title":"Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety","volume":"84","author":"Kyllonen","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00007890-199807150-00005","article-title":"Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes following renal transplant","volume":"66","author":"Gaber","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1432-2277.2004.tb00469.x","article-title":"Polyclonal anti-thymocyte globulins influence apoptosis in reperfused tissues after ischaemia in a non-human primate model","volume":"17","author":"Beiras-Fernandez","year":"2004","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2016.11.004_bb0110","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/00007890-199911270-00032","article-title":"Campath 1H allows low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients","volume":"68","author":"Calne","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0115","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.surg.2004.06.015","article-title":"Campath-1H in renal transplantation: the University of Wisconsin experience","volume":"136","author":"Knechtle","year":"2004","journal-title":"Surgery"},{"key":"10.1016\/j.trim.2016.11.004_bb0120","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/01.TP.0000128625.29654.EB","article-title":"The use of Campath-1H as induction therapy in renal transplantation: preliminary results","volume":"78","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0125","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1111\/j.1600-6143.2005.01067.x","article-title":"Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction \u2013 long-term results","volume":"5","author":"Kaufman","year":"2005","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2016.11.004_bb0130","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1097\/TP.0b013e31816f60cf","article-title":"Campath induction for kidney transplantation: report of 297 cases","volume":"85","author":"Ortiz","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0135","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":"Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial","volume":"8","author":"Margreiter","year":"2008","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2016.11.004_bb0140","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/TP.0b013e3181b4acfb","article-title":"A randomized trial of alemtuzumab vs. antithymocyte globulin induction in renal and pancreas transplantation","volume":"88","author":"Farney","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0145","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/TP.0b013e31822ca7ca","article-title":"Kidney transplantation with minimized maintenance: Alemtuzumab induction with tacrolimus monotherapy \u2013 an open label, randomized trial","volume":"92","author":"Chan","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0150","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2016.11.004_bb0155","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/j.1600-6143.2011.03891.x","article-title":"An analysis of lymphocyte phenotype after steroid avoidance with either alemtuzumab or basiliximab induction in renal transplantation","volume":"12","author":"Cherukuri","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2016.11.004_bb0160","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/TP.0b013e318257ad41","article-title":"Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis","volume":"93","author":"Morgan","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0165","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Daclizumab Triple Therapy Study Group, Interleukin-2-Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation","volume":"338","author":"Vincenti","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2016.11.004_bb0170","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00007890-199901150-00019","article-title":"Daclizumab Double Therapy Study Group, Reduction of Acute Renal Allograft Rejection by Daclizumab","volume":"67","author":"Nashan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0175","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/00007890-200204150-00015","article-title":"Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recpients","volume":"73","author":"Ciancio","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0180","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.trim.2016.11.004_bb0185","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1097\/TP.0b013e3181d02496","article-title":"Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study","volume":"89","author":"Kandus","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0190","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.trim.2016.11.004_bb0195","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00007890-199901270-00016","article-title":"Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1034\/j.1600-6143.2002.020109.x","article-title":"Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy","volume":"2","author":"Lebranchu","year":"2002","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2016.11.004_bb0205","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/01.TP.0000129812.68794.CC","article-title":"Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids","volume":"78","author":"Mourad","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0210","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1600-6143.2007.02134.x","article-title":"CD4+CD25+FOXP3+ regulatroy T cells increase de novo in kidney transplant patients after imunodepletion with Campath-1H","volume":"8","author":"Bloom","year":"2008","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2016.11.004_bb0215","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1681\/ASN.2006050422","article-title":"A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells","volume":"17","author":"Lopez","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2016.11.004_bb0220","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1111\/j.1600-6143.2010.03210.x","article-title":"Immune reconstitution following rabbit antithymocyte globulin","volume":"10","author":"Gurkan","year":"2010","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2016.11.004_bb0225","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1600-6143.2006.01604.x","article-title":"Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients","volume":"7","author":"Kreijveld","year":"2007","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2016.11.004_bb0230","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/S0041-1345(02)03149-4","article-title":"Can acute rejection be prevented in SPK transplantation?","volume":"34","author":"Burke","year":"2002","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2016.11.004_bb0235","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/S0041-1345(02)03122-6","article-title":"Steroid-resistant acute rejection following SPK: importance of maintaining therapeutic dosing in a triple-drug regimen","volume":"34","author":"Burke","year":"2002","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2016.11.004_bb0240","doi-asserted-by":"crossref","first-page":"546","DOI":"10.2215\/CJN.01841105","article-title":"Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation","volume":"1","author":"Ruggenenti","year":"2006","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2016.11.004_bb0245","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.transproceed.2010.03.073","article-title":"Induction with basiliximab plus thymoglobulin is effective and safe in old-for-old renal transplantation: six-month results of a prospective clinical study","volume":"42","author":"Favi","year":"2010","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2016.11.004_bb0250","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.trim.2011.07.002","article-title":"Prolonged lymphocyte depletion by single-dose rabbit anti-thymocyte globulin and alemtuzumab in kidney transplantation","volume":"25","author":"Sageshima","year":"2011","journal-title":"Transplant. Immunol."},{"key":"10.1016\/j.trim.2016.11.004_bb0255","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1097\/TP.0b013e3182384b21","article-title":"Randomized trial of dual antibody induction therapy with steroid avoidance in renal transplantation","volume":"92","author":"Ciancio","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0260","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/TP.0b013e3181f2c962","article-title":"Favorable outcomes with machine perfusion and longer pump times in kidney transplantation: a single-center, observational study","volume":"90","author":"Ciancio","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0265","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.trim.2016.11.004_bb0270","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1600-6143.2008.02159.x","article-title":"Banff 07 classification of renal allograft pathology: updates and future directions","volume":"8","author":"Solez","year":"2008","journal-title":"Am. J. Transplant."},{"issue":"S1","key":"10.1016\/j.trim.2016.11.004_bb0275","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc11-S062","article-title":"Diagnosis and classification of diabetes mellitus","volume":"34","author":"American Diabetes Association","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trim.2016.11.004_bb0280","series-title":"Statistical Methods","author":"Snedecor","year":"1967"},{"key":"10.1016\/j.trim.2016.11.004_bb0285","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/00007890-199403270-00015","article-title":"The impact of an acute rejection episode on long-term renal allograft survival (t1\/2)","volume":"57","author":"Matas","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0290","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(14)61095-3","article-title":"Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C study): a randomised trial","volume":"384","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.trim.2016.11.004_bb0295","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00007890-200202150-00025","article-title":"Short course induction immunosuppression with thymoglobulin for renal transplant recipients","volume":"73","author":"Agha","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0300","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1097\/TP.0b013e3181722fad","article-title":"Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report","volume":"85","author":"Stevens","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2016.11.004_bb0305","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.trim.2013.03.001","article-title":"Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial","volume":"28","author":"Buchler","year":"2013","journal-title":"Transplant. Immunol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327416301290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327416301290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T09:28:06Z","timestamp":1536226086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327416301290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":61,"alternative-id":["S0966327416301290"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2016.11.004","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2017,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Randomized trial of rATg\/Daclizumab vs. rATg\/Alemtuzumab as dual induction therapy in renal transplantation: Results at 8years of follow-up","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2016.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}